Precision oncology is increasing relying on genetic testing and laboratories frequently develop targeted tests that include hundreds of cancer-related genes. This session will highlight the relative advantages and limitations of targeted (selected gene panel) vs. comprehensive (exome and genome) genetic testing. This session will be presented as a “point-counterpoint” with each speaker focusing on the opportunities of genetic tests in molecular oncology using specific clinical applications such as pediatric brain cancer as illustrative case examples. The presentations will be followed by a panel discussion and Q&A session.
Big Data and Little Patients: Targeted Sequencing for Pediatric Brain Tumors
Sarah Leary, MD, MS, Seattle Children's Hospital, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Bigger is Better: More Cancer Genes in More Patients
Wendy Chung, MD, PhD, Columbia University, New York, NY, USA
Objectives:
- Discuss the benefits of next-generation sequencing in oncology.
- Recognize the need for both targeted and comprehensive tests.
- Describe advantages of targeted testing in pediatric oncology..
Duration: 1.00 hr
Recording Date: November 7, 2019
CME/CMLE credit: 1.00 hr
Last day to purchase course and CE claim credit: December 24, 2022
